Form 4: VolitionRx Director Ethel Rubin Acquires Restricted Stock Units in Lieu of Cash Compensation

Director Ethel Rubin acquired 9,893 restricted stock units (RSUs) in VolitionRx Ltd (VNRX) on March 1, 2025, in lieu of cash compensation.

Summary

• On March 1, 2025, Ethel Rubin, a director of VolitionRx Ltd (VNRX), acquired 9,893 restricted stock units (RSUs).
• The RSUs were awarded under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation.
• The RSUs vest in three installments: 3,298 units on March 1, 2025, 3,298 units on April 1, 2025, and 3,297 units on May 1, 2025.
• The RSUs are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting and settlement, Rubin will receive shares of common stock equal to the number of RSUs that have vested.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and alignment of director interests with shareholders.

Positives

• The acquisition of RSUs by a director demonstrates alignment with the company's long-term success.

Industry Context

This type of equity compensation is common in the biotech industry to attract and retain talent, especially at the director level.

Comparison to Industry Standards

• Granting RSUs to directors is a standard practice among publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders.
• The vesting schedule of the RSUs, with installments over a period of one year, is also typical for such grants.

Stakeholder Impact

• The granting of RSUs aligns the director's interests with those of the shareholders, potentially leading to better decision-making for the company's long-term success.

Key Dates